Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: The Association Between Patient-Reported and Clinician-Reported Outcomes at Week 16 in a Phase 3b/4 Multicenter, Randomized, Double-blinded, Placebo-controlled Study (PSORIATYK SCALP). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 2, p. s528, 2025. DOI: 10.25251/skin.10.supp.528. Disponível em: https://skin.dermsquared.com/skin/article/view/3310. Acesso em: 25 jun. 2025.